Filing Flows › Monte Rosa Therapeutics (GLUE) › Q4 2025
Monte Rosa Therapeutics (GLUE) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 17, 2026
Monte Rosa Therapeutics (GLUE) reported revenue of $2.8M for the fourth quarter 2025 (Q4 2025), -95% from a year earlier and -78% from the quarter before.
Monte Rosa Therapeutics, Q4 2025: revenue $2.8M (-95% year over year), net loss $46.1M, operating cash flow −$43.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.8M | -78% | -95% |
| Operating profit | −$49.7M | — | — |
| Net earnings | −$46.1M | — | — |
| Operating cash flow | −$43.0M | -143% | — |
What changed
Revenue was $2.8M in Q4 2025, down 95% year over year and down 78% from the previous quarter.
Operating costs exceeded revenue by $49.7M, an operating margin of -1787.7%. Total costs grew 10% against a revenue fall of 95%. The fastest-growing cost line was General & admin (+20%). The quarter ended with a net loss of $46.1M, wider than the previous quarter's $27.1M loss. Minority interests bore $26K of it: to shareholders the quarter was a loss of $46.1M.
Operating cash flow was −$43.0M. Non-cash charges added back $2.8M of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items used $3.9M. Capital expenditures of $767K exceeded it, leaving free cash flow of −$43.8M.
Questions
What was Monte Rosa Therapeutics' revenue in the fourth quarter 2025?
Monte Rosa Therapeutics (GLUE) reported revenue of $2.8M for the fourth quarter 2025 (Q4 2025), -95% from a year earlier and -78% from the quarter before.